Elizabeth Holmes, the former CEO of Theranos, is involved with a new health tech startup called Haemanthus while serving an 11-year prison sentence for fraud. Her partner, Billy Evans, has raised millions to fund the venture, which aims to create artificial intelligence products for medical testing. Despite her conviction, Holmes is advising Evans and plans to return to the biotechnology field post-incarceration.
Haemanthus, which employs photodetection technology and Raman spectroscopy, aims to make diagnostic testing more accessible and affordable. The startup seeks to use small biological samples, such as sweat and saliva, for medical testing. Presently, the company is in its infancy, with further product developments underway. Sources indicate that Holmes’s involvement will not be formal, given restrictions on her serving in public company roles due to a previous SEC investigation.
Source link
